New York State Teachers Retirement System lowered its position in Amgen, Inc. (NASDAQ:AMGN) by 2.0% during the fourth quarter, Holdings Channel reports. The firm owned 1,376,197 shares of the medical research company’s stock after selling 27,551 shares during the period. New York State Teachers Retirement System’s holdings in Amgen were worth $201,214,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Nations Financial Group Inc. IA ADV bought a new stake in Amgen during the fourth quarter valued at $252,000. Ally Financial Inc. bought a new stake in Amgen during the fourth quarter valued at $2,632,000. Greenwood Capital Associates LLC increased its stake in Amgen by 3.9% in the fourth quarter. Greenwood Capital Associates LLC now owns 13,981 shares of the medical research company’s stock valued at $2,044,000 after buying an additional 527 shares during the last quarter. Lyell Wealth Management LP bought a new stake in Amgen during the fourth quarter valued at $1,817,000. Finally, Employees Retirement System of Texas increased its stake in Amgen by 20.3% in the fourth quarter. Employees Retirement System of Texas now owns 222,500 shares of the medical research company’s stock valued at $32,532,000 after buying an additional 37,500 shares during the last quarter. Hedge funds and other institutional investors own 79.04% of the company’s stock.
Amgen, Inc. (NASDAQ:AMGN) opened at 169.24 on Tuesday. The company has a market capitalization of $124.64 billion, a PE ratio of 16.53 and a beta of 1.15. Amgen, Inc. has a 12-month low of $133.64 and a 12-month high of $184.21. The stock’s 50 day moving average price is $171.88 and its 200 day moving average price is $159.85.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, February 2nd. The medical research company reported $2.89 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.79 by $0.10. The company had revenue of $5.97 billion for the quarter, compared to analyst estimates of $5.75 billion. Amgen had a net margin of 33.59% and a return on equity of 29.42%. Amgen’s revenue was up 7.7% compared to the same quarter last year. During the same period last year, the company posted $2.61 earnings per share. On average, equities analysts anticipate that Amgen, Inc. will post $12.31 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 8th. Investors of record on Wednesday, May 17th will be issued a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a yield of 2.72%. The ex-dividend date is Monday, May 15th. Amgen’s payout ratio is 44.92%.
Your IP Address:
Several research firms recently weighed in on AMGN. Goldman Sachs Group Inc cut their price target on Amgen from $208.00 to $202.00 and set a “conviction-buy” rating on the stock in a research note on Monday. Vetr upgraded Amgen from a “sell” rating to a “hold” rating and set a $174.10 price target on the stock in a research note on Monday. Robert W. Baird restated a “neutral” rating and issued a $165.00 price target on shares of Amgen in a research note on Friday. Cowen and Company restated a “buy” rating and issued a $209.00 price target on shares of Amgen in a research note on Friday. Finally, Mizuho set a $195.00 price target on Amgen and gave the stock a “buy” rating in a research note on Thursday, March 16th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $187.41.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.